Vera Therapeutics (VERA) announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. Before joining Vera Therapeutics, Skelton scaled the commercial organization at Seagen.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Buy Rating on Vera: De-Risked Atacicept Approval Path and Large IgA Nephropathy Market Drive Compelling Upside into 2026 Catalysts
- Vera Therapeutics announces atacicept BLA accepted for Priority Review by FDA
- Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’
- Short Report: Vera Therapeutics bears retreat as stock rallies
- Vera Therapeutics price target raised to $66 from $48 at BofA